A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia

Inclusion Criteria: * Participants meeting Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis criteria of schizophrenia * Participant receiving full course of treatment (6-8 weeks) at correct dose (dose range recommended by the instruction) of Risperdal, Zyprexa or Seroquel before enrollment, was poorly controlled and had to change medication because of unsatisfying efficacy, tolerability or safety issues, or other reason * Participant in the non-acute phase during screening received treatment with any of above three antipsychotics within 4 weeks before enrollment and state of illness was relatively stable * 7\. Female participants must be postmenopausal for at least 1 year, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of birth control before entry and throughout the study. Effective methods of birth control include prescription hormonal contraceptives, contraceptive injections, intrauterine devices, double barrier method, contraceptive patch and male partner sterilization. Female participants must also have a negative urine pregnancy test at screening * Participant willing to and who could complete questionnaire by himself Exclusion Criteria: * Participant receiving treatment with clozapine or risperidone microspheres for injection (Hengde) within 3 months before screening * Participant having history of seizure except febrile convulsion (seizures that occur during a febrile episode \[fever\]) * Part…